## **CLAIMS**

1. The use of a compound of general formula (I)

$$R^2$$
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^4$ 
 $R^4$ 

wherein

R is an aryl group selected from phenyl or benzyl, which is optionally substituted with a  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, halogen, hydroxyl, amino, nitro, amido, nitrile or a carboxyl group;

R<sup>1</sup> is C<sub>1-6</sub> alkyl or hydrogen;

 $R^2$  is  $C_{1\text{-}6}$  alkoxy, hydrogen, hydroxyl, or halogen; and

 $R^3$  is  $C_{1-6}$  alkoxy, hydrogen, hydroxyl, or halogen,

for the manufacture of a medicament for the treatment of dyskinesia.

2. The use according to claim 1, wherein R is selected from the following groups:

- 3. The use according to claim 1 or 2, wherein when  $R^1$  is an alkyl group it is  $C_2$  alkyl (ethyl).
- 4. The use according to claim 1, 2 or 3, wherein when  $R^2$  is an alkoxy group, it is  $C_1$  alkoxy (methoxy).
- 5. The use according to any one of the preceding claims, wherein when  $R^3$  is an alkoxy group, it is  $C_1$  alkoxy (methoxy).
- 6. The use according to any one of the preceding claims, wherein the compound of formula I is selected from the group comprising Tofisopam, Girisopam and Nerisopam (shown below):

31

- 7. The use according to claim 6, wherein the compound of formula I is Tofisopam.
- 8. The use according to any preceding claim, for the treatment of dyskinesia associated with movement disorders.
- 9. The use according to claim 8, for the treatment of dyskinesia associated with parkinsonism.
- The use according to claim 9 wherein the parkinsonism is idiopathic
   Parkinson's disease or post-encephalitic parkinsonism.
- 11. The use according to claim 9 wherein the parkinsonism results from head injury, the treatment of schizophrenia, drug intoxication or manganese poisoning.
- 12. The use according to any one of claims 1 7 for the treatment of dyskinesia associated with Huntington's disease, idiopathic torsion dystonia, or off-dystonia in Parkinson's disease.
- 13. The use according to anyone of claims 1-7 for the treatment of hyperkinetic disorder associated with Tourette's syndrome and ADHD.

- 14. The use according to any one of claims 1 7 for the treatment of dyskinesia which arises as a side-effect of a therapeutic agent.
- 15. The use according to claim 14 for the treatment of dyskinesia associated with agents used to treat movement disorders.
- 16. The use according to claim 14 or 15 wherein the agent is used to treat parkinsonism.
- 17. The use according to claim 16 wherein the agent is a dopamine precursor.
- 18. The use according to claim 16 wherein the agent is a dopamine receptor agonist.
- 19. The use according to claim 16 wherein the agent in L-DOPA.
- 20. The use according to claim 16 wherein the agent is one of Chloro-APB, apomorphine, ropinirole, pramipexole, cabergoline, bromcriptine, lisuride or pergolide.
- 21. The use according to claim 14 wherein the agent is used to treat schizophrenia or other psychosis.
- 22. The use according to claim 21 wherein the agent is a neuroleptic.
- 23. The use according to claim 21 wherein the agent has dopamine receptor antagonist properties.
- 24. The use according to claim 21 wherein the agent is haloperidol clozapine, fluphenazine or sulpiride.
- 25. The use according to any preceding claim for prophylactic treatment.